Artelo Biosciences, Inc. (ARTL) Stock Score, Valuation & Financial Research

Artelo Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ARTL

Artelo Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.46. These figures are a research snapshot, not a buy or sell recommendation.

What Artelo Biosciences, Inc. does

Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Artelo Biosciences is a clinical-stage pharmaceutical company that generates no revenue from product sales. Its business model relies on raising capital through equity and debt offerings to fund the research, development, and potential future commercialization of proprietary therapeutics that modulate lipid-signaling pathways.

Products and services

  • The company is developing a portfolio of product candidates including ART26.12 (a Fatty Acid Binding Protein inhibitor), ART27.13 (a dual cannabinoid receptor agonist), and ART12.11 (a synthetic cannabidiol analog) for conditions such as cancer, pain, and dermatologic disorders.

Customer types

Patients with cancer, pain, dermatologic, or neurological conditions.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes various third-party contract research organizations to conduct clinical trials and preclinical studies; specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary portfolio of lipid-signaling pathway modulators Source

Business risks and research considerations

  • History of operating losses and dependence on future financing Source
  • Clinical trial failure and regulatory approval uncertainty Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ARTL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.46
Market capitalization:
1.34M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -12.67M
Free cash flow:
USD -8.52M
Cash:
USD 4.2M
Total debt:
USD 49K
EPS:
USD -74.28

What stands out

  • Free cash flow is USD -8.52M, negative for the stored period.
  • The balance sheet shows USD 4.2M of cash versus USD 49K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 4.15M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ARTL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ARTL fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ARTL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ARTL to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ARTL's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research ARTL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.